KR102843447B1 - 항암제의 투여에 수반되는 장애를 치료 또는 예방하기 위한 의약 조성물 - Google Patents

항암제의 투여에 수반되는 장애를 치료 또는 예방하기 위한 의약 조성물

Info

Publication number
KR102843447B1
KR102843447B1 KR1020237038088A KR20237038088A KR102843447B1 KR 102843447 B1 KR102843447 B1 KR 102843447B1 KR 1020237038088 A KR1020237038088 A KR 1020237038088A KR 20237038088 A KR20237038088 A KR 20237038088A KR 102843447 B1 KR102843447 B1 KR 102843447B1
Authority
KR
South Korea
Prior art keywords
cancer
sod
superoxide dismutase
pharmaceutical composition
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237038088A
Other languages
English (en)
Korean (ko)
Other versions
KR20240008844A (ko
Inventor
지웨이 차오
마나미 혼다
쇼우타 아키모토
도모키 사사키
노리코 가지
고이치로 후쿠다
도루 미즈시마
겐이치로 다나카
Original Assignee
가부시키가이샤 엘티티 바이오파마
각코우호우징 무사시노 다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 엘티티 바이오파마, 각코우호우징 무사시노 다이가쿠 filed Critical 가부시키가이샤 엘티티 바이오파마
Publication of KR20240008844A publication Critical patent/KR20240008844A/ko
Application granted granted Critical
Publication of KR102843447B1 publication Critical patent/KR102843447B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237038088A 2021-05-18 2022-05-17 항암제의 투여에 수반되는 장애를 치료 또는 예방하기 위한 의약 조성물 Active KR102843447B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-083610 2021-05-18
JP2021083610 2021-05-18
PCT/JP2022/020473 WO2022244757A1 (ja) 2021-05-18 2022-05-17 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Publications (2)

Publication Number Publication Date
KR20240008844A KR20240008844A (ko) 2024-01-19
KR102843447B1 true KR102843447B1 (ko) 2025-08-06

Family

ID=84141593

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237038088A Active KR102843447B1 (ko) 2021-05-18 2022-05-17 항암제의 투여에 수반되는 장애를 치료 또는 예방하기 위한 의약 조성물

Country Status (11)

Country Link
US (1) US20240261375A1 (https=)
EP (1) EP4353251A4 (https=)
JP (1) JP7504367B2 (https=)
KR (1) KR102843447B1 (https=)
CN (1) CN117279657A (https=)
AU (1) AU2022278242B2 (https=)
CA (1) CA3220333A1 (https=)
CO (1) CO2023017275A2 (https=)
MX (1) MX2023013777A (https=)
TW (1) TWI867299B (https=)
WO (1) WO2022244757A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025178511A1 (ru) * 2024-02-21 2025-08-28 Евгений Владимирович ГРИГОРЬЕВ Применение супероксиддисмутазы 2 в качестве антиоксиданта в сверхмалых дозировках

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101183856B1 (ko) * 2004-10-12 2012-09-19 가부시키가이샤 엘티티 바이오파마 레시틴화 수퍼옥사이드 디스뮤타아제 조성물 및 그 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653670B2 (ja) * 1985-10-28 1994-07-20 日研フ−ド株式会社 化学療法剤の副作用低減化剤
JPH04135485A (ja) * 1990-09-28 1992-05-08 Seikagaku Kogyo Co Ltd 白金錯体及び抗腫瘍剤
JP3232542B2 (ja) 1993-01-08 2001-11-26 宇部興産株式会社 ヒトＣｕ，Ｚｎ型スーパーオキシドジスムターゼ誘導体及びその製造法
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
US6221848B1 (en) * 1998-05-11 2001-04-24 University Of Pittsburgh Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
JP2001002585A (ja) * 1999-06-22 2001-01-09 Ltt Kenkyusho:Kk レシチン化スーパーオキシドジスムターゼ含有抗線維化剤
JP3792487B2 (ja) 1999-06-24 2006-07-05 株式会社Ｌｔｔバイオファーマ レシチン化スーパーオキシドジスムターゼ含有医薬組成物
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
JP2002080395A (ja) * 2000-08-31 2002-03-19 Ltt Institute Co Ltd 心筋傷害処置剤
ES2375797T3 (es) 2003-01-21 2012-03-06 Genervon Biopharmaceuticals Llc Péptidos y compuestos de factores tróficos de motoneuronas y sus procedimientos de utilización.
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
JP2006169128A (ja) 2004-12-13 2006-06-29 Ltt Bio-Pharma Co Ltd 熱傷治療剤
JP4867540B2 (ja) 2006-09-20 2012-02-01 日本精工株式会社 無段変速装置
US20100143321A1 (en) * 2006-12-19 2010-06-10 Ltt Bio Pharma Co., Ltd. Therapeutic composition for interstitual pneumonia
JP5459827B2 (ja) 2009-03-13 2014-04-02 株式会社Ｌｔｔバイオファーマ 慢性閉塞性肺疾患改善剤
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9187509B2 (en) 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
JP6545926B2 (ja) * 2012-11-30 2019-07-17 株式会社ナノエッグ 手足症候群治療用組成物
RU2017106172A (ru) 2014-07-31 2018-08-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn)
EP2985036A3 (en) 2014-08-14 2016-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. CYP2J2 antagonists in the treatment of pain
US11197862B2 (en) 2015-07-16 2021-12-14 Xomics Biopharma, Inc. Methods of preventing toxicity of platinum drugs
JP6650612B2 (ja) 2015-10-06 2020-02-19 パナソニックＩｐマネジメント株式会社 照明制御装置及び照明システム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101183856B1 (ko) * 2004-10-12 2012-09-19 가부시키가이샤 엘티티 바이오파마 레시틴화 수퍼옥사이드 디스뮤타아제 조성물 및 그 제조방법

Also Published As

Publication number Publication date
EP4353251A1 (en) 2024-04-17
CN117279657A (zh) 2023-12-22
US20240261375A1 (en) 2024-08-08
JP7504367B2 (ja) 2024-06-24
AU2022278242B2 (en) 2024-11-14
CO2023017275A2 (es) 2023-12-20
MX2023013777A (es) 2023-12-04
TW202313100A (zh) 2023-04-01
WO2022244757A1 (ja) 2022-11-24
KR20240008844A (ko) 2024-01-19
JPWO2022244757A1 (https=) 2022-11-24
BR112023024140A2 (pt) 2024-02-06
TWI867299B (zh) 2024-12-21
AU2022278242A1 (en) 2023-11-30
EP4353251A4 (en) 2025-05-14
CA3220333A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
Hu et al. E Platinum, a newly synthesized platinum compound, induces autophagy via inhibiting phosphorylation of mTOR in gastric carcinoma BGC-823 cells
Qian et al. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents
JP2018508196A (ja) 抗老化化合物及びその使用
US11622990B2 (en) VAP polypeptide and use thereof in preparation of drug for targeted diagnosis and treatment of tumor
Riccardi et al. “Dressing up” an old drug: An aminoacyl lipid for the functionalization of Ru (III)-based anticancer agents
Wei et al. Proanthocyanidin capsules remodel the ROS microenvironment via regulating MAPK signaling for accelerating diabetic wound healing
KR102843447B1 (ko) 항암제의 투여에 수반되는 장애를 치료 또는 예방하기 위한 의약 조성물
Zhan et al. Semen Strychni Pulveratum and vomicine alleviate neuroinflammation in amyotrophic lateral sclerosis through cGAS-STING-TBK1 pathway
KR102228272B1 (ko) 항암 상승효과를 나타내는 종양세포 특이적 자기조립 나노약물 복합체
Fan et al. Synthesis and biological evaluation of gold nanoparticles drug delivery system for anti-rheumatoid arthritis agents
Li et al. A novel antibody-KSP inhibitor conjugate improves KSP inhibitor efficacy in vitro and in vivo
CN114621325A (zh) 一种纤连蛋白靶向多肽及其在促进肿瘤失巢凋亡及化疗增敏中的应用
RU2845522C2 (ru) Фармацевтическая композиция для лечения или профилактики расстройства, связанного с введением противоракового средства
Li et al. Long-circulating liposomal delivery system targeting at PDGFR-β enhances the therapeutic effect of IFN-α on hepatic fibrosis
EP3714881A1 (en) Combination product comprising dicycloplatin and preparation method and use thereof
KR102230514B1 (ko) 글리아딘 펩타이드를 사용한 암 치료용 키트 및 방법
WO2022211027A1 (ja) Ｃｄ９シグナル抑制剤及びその使用
Liu et al. A fluorinated prodrug strategy enhances the therapeutic index of nanoparticle-delivered hydrophilic drugs
BR112023024140B1 (pt) Uso de uma superóxido dismutase lecitinizada para tratar ou prevenir um distúrbio associado com a administração de um agente anticâncer
HK40100859A (zh) 用於治疗或预防伴随抗癌剂给药的障碍的医药组合物
CN112294829A (zh) 红景天苷在制备治疗或预防癌症的药物中的应用
CN119331026B (zh) 一种具有瑞格列奈四价铂结构的衍生物及其制备方法和用途
US20240009212A1 (en) Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof
Li et al. “Capture and kill” circulating fibrocytes by cisplatin prodrug loaded albumin disrupt the progress of pulmonary fibrosis in mice
Sun et al. Myristoyl-modified BMAP-28m affects the cell cycle and apoptosis of prostate cancer cells by damaging the cell membrane

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)